DK2470199T3 - Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase - Google Patents

Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase Download PDF

Info

Publication number
DK2470199T3
DK2470199T3 DK10812683.0T DK10812683T DK2470199T3 DK 2470199 T3 DK2470199 T3 DK 2470199T3 DK 10812683 T DK10812683 T DK 10812683T DK 2470199 T3 DK2470199 T3 DK 2470199T3
Authority
DK
Denmark
Prior art keywords
enzymer
treatment
replacement therapy
acid sphingomyelinase
dosage increase
Prior art date
Application number
DK10812683.0T
Other languages
English (en)
Inventor
Edward H Schuchman
Robert J Desnick
Gerald F Cox
Laura P Andrews
James M Murray
Original Assignee
Icahn School Med Mount Sinai
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2470199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icahn School Med Mount Sinai, Genzyme Corp filed Critical Icahn School Med Mount Sinai
Application granted granted Critical
Publication of DK2470199T3 publication Critical patent/DK2470199T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
DK10812683.0T 2009-08-28 2010-08-28 Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase DK2470199T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number Publication Date
DK2470199T3 true DK2470199T3 (da) 2019-08-05

Family

ID=43625265

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18199358.5T DK3482767T3 (da) 2009-08-28 2010-08-28 Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
DK10812683.0T DK2470199T3 (da) 2009-08-28 2010-08-28 Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18199358.5T DK3482767T3 (da) 2009-08-28 2010-08-28 Dosisoptrapningsenzymerstatningsterapi til behandling af mangel på sur sphingomyelinase

Country Status (26)

Country Link
US (9) US8349319B2 (da)
EP (3) EP3998078A1 (da)
JP (7) JP5955219B2 (da)
KR (5) KR102094253B1 (da)
CN (3) CN102596232A (da)
AU (5) AU2010286550B2 (da)
BR (1) BR112012004377A2 (da)
CA (1) CA2773133A1 (da)
CL (1) CL2012000495A1 (da)
CY (1) CY1122128T1 (da)
DK (2) DK3482767T3 (da)
ES (2) ES2902229T3 (da)
FR (1) FR22C1062I2 (da)
HR (2) HRP20211992T1 (da)
HU (3) HUE046598T2 (da)
IL (3) IL300625A (da)
LT (2) LT2470199T (da)
MX (1) MX356873B (da)
NL (1) NL301211I2 (da)
PL (2) PL2470199T3 (da)
PT (2) PT3482767T (da)
RU (3) RU2731616C2 (da)
SI (2) SI3482767T1 (da)
TR (1) TR201911293T4 (da)
WO (1) WO2011025996A2 (da)
ZA (2) ZA201201435B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
WO2008154198A1 (en) 2007-06-06 2008-12-18 Genzyme Corporation Gene therapy for lysosomal storage diseases
SI3482767T1 (sl) * 2009-08-28 2022-03-31 Icahn School Of Medicine At Mount Sinai Encimska nadomestna terapija s povečevanjem odmerkov za zdravljenje pomanjkanja kisle sfingomielinaze
US8882701B2 (en) * 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
WO2011146143A2 (en) 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity
WO2012129084A2 (en) 2011-03-18 2012-09-27 Genzyme Corporation Glucosylceramide synthase inhibitors
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
JP6243846B2 (ja) 2011-11-15 2017-12-06 セントジーン アーゲー ニーマン・ピック病の診断のための方法
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
DK2968479T3 (da) 2013-03-14 2019-08-12 Icahn School Med Mount Sinai Terapeutiske sure ceramidasesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP2997384B1 (en) * 2013-05-14 2019-04-10 Centogene AG Method for the diagnosis of niemann-pick disease
MY185990A (en) * 2013-06-07 2021-06-14 Genzyme Corp Marker for acid sphingomyelinase disorders and uses thereof
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
US11898175B2 (en) 2017-08-24 2024-02-13 Genzyme Corporation Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
TW201925236A (zh) 2017-10-02 2019-07-01 美商戴納立製藥公司 包含酶替代療法酶之融合蛋白
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) * 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
AU776855B2 (en) 1998-12-23 2004-09-23 Boyce Thompson Institute For Plant Research Inc. Expression of immunogenic hepatitis B surface antigens in transgenic plants
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AR034413A1 (es) * 2000-08-25 2004-02-25 Nestor Abel Chamoles Metodo para determinar la actividad de las enzimas lisosomales
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7396811B2 (en) 2001-04-30 2008-07-08 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
US7658916B2 (en) * 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
BRPI0411291A (pt) 2003-06-12 2006-08-01 Genzyme Corp esfingomielinase acida humana modificada tendo atividade aumentada e métodos para a fabricação da mesma
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1691819A4 (en) 2003-11-25 2009-05-06 Sinai School Medicine THERAPY ON CHAPERON BASIS FOR NIEMANN PICK DISEASE
WO2006040764A2 (en) 2004-10-13 2006-04-20 Protalix Ltd. System and method for production of antibodies in plant cell culture
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2009519713A (ja) 2005-12-15 2009-05-21 ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク 血漿中及び組織中のスフィンゴエミリン及びホスファチジルコリンの酵素的測定方法
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
WO2007091250A2 (en) 2006-02-06 2007-08-16 The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
DK1988823T3 (da) * 2006-02-09 2018-12-03 Genzyme Corp Langsom intraventrikulær administration
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
CN105879047A (zh) 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
SI3482767T1 (sl) * 2009-08-28 2022-03-31 Icahn School Of Medicine At Mount Sinai Encimska nadomestna terapija s povečevanjem odmerkov za zdravljenje pomanjkanja kisle sfingomielinaze
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法

Also Published As

Publication number Publication date
US20140335070A1 (en) 2014-11-13
LT3482767T (lt) 2022-01-10
NL301211I2 (nl) 2023-02-02
AU2016216625B2 (en) 2018-07-05
WO2011025996A9 (en) 2011-08-25
US8709408B2 (en) 2014-04-29
DK3482767T3 (da) 2021-12-20
EP2470199A2 (en) 2012-07-04
US20110052559A1 (en) 2011-03-03
FR22C1062I1 (fr) 2023-02-03
JP2018076322A (ja) 2018-05-17
NL301211I1 (nl) 2022-12-28
LT2470199T (lt) 2019-10-10
IL218324B (en) 2019-05-30
JP2022003065A (ja) 2022-01-11
SI3482767T1 (sl) 2022-03-31
RU2731616C2 (ru) 2020-09-07
JP6952810B2 (ja) 2021-10-20
US20220305091A1 (en) 2022-09-29
IL266915B1 (en) 2023-03-01
JP2016153408A (ja) 2016-08-25
JP7167281B2 (ja) 2022-11-08
PT3482767T (pt) 2021-12-29
US20160120957A1 (en) 2016-05-05
HRP20211992T1 (hr) 2022-04-01
EP3998078A1 (en) 2022-05-18
US20180055916A1 (en) 2018-03-01
ZA201201435B (en) 2020-05-27
HUE046598T2 (hu) 2020-03-30
EP3482767A1 (en) 2019-05-15
IL300625A (en) 2023-04-01
MX356873B (es) 2018-06-18
IL266915B2 (en) 2023-07-01
JP2013502933A (ja) 2013-01-31
RU2015145255A (ru) 2019-01-11
CN105999238A (zh) 2016-10-12
EP2470199B1 (en) 2019-05-22
KR20210107153A (ko) 2021-08-31
WO2011025996A3 (en) 2012-03-15
AU2018204156A1 (en) 2018-06-28
HRP20191385T1 (hr) 2019-11-01
US8349319B2 (en) 2013-01-08
IL218324A0 (en) 2012-04-30
US20130078230A1 (en) 2013-03-28
US9114139B2 (en) 2015-08-25
EP3482767B1 (en) 2021-10-06
BR112012004377A2 (pt) 2017-12-12
WO2011025996A2 (en) 2011-03-03
TR201911293T4 (tr) 2019-08-21
CL2012000495A1 (es) 2014-02-07
EP2470199A4 (en) 2013-03-27
HUE057440T2 (hu) 2022-05-28
RU2569744C2 (ru) 2015-11-27
AU2020256322B2 (en) 2024-02-29
KR102608551B1 (ko) 2023-12-04
JP5955219B2 (ja) 2016-07-20
US8658162B2 (en) 2014-02-25
CN106047835A (zh) 2016-10-26
AU2010286550A1 (en) 2012-03-15
JP2024026214A (ja) 2024-02-28
KR20220104271A (ko) 2022-07-26
JP7395693B2 (ja) 2023-12-11
ES2738859T3 (es) 2020-01-27
PL3482767T3 (pl) 2022-02-14
KR20230164773A (ko) 2023-12-04
AU2010286550B2 (en) 2016-05-19
US10188705B2 (en) 2019-01-29
CA2773133A1 (en) 2011-03-03
AU2016216625A1 (en) 2016-09-15
JP6251307B2 (ja) 2017-12-20
CY1122128T1 (el) 2020-11-25
US20190151419A1 (en) 2019-05-23
IL266915A (en) 2019-07-31
HUS2200050I1 (hu) 2022-12-28
RU2020128994A (ru) 2022-03-02
PL2470199T3 (pl) 2019-11-29
KR20200034828A (ko) 2020-03-31
RU2012111823A (ru) 2013-10-10
AU2020256322A1 (en) 2020-11-12
KR102094253B1 (ko) 2020-03-31
CN102596232A (zh) 2012-07-18
MX2012002449A (es) 2012-03-14
FR22C1062I2 (fr) 2023-12-29
AU2024201085A1 (en) 2024-03-07
US9655954B2 (en) 2017-05-23
AU2018204156B2 (en) 2020-07-16
SI2470199T1 (sl) 2019-11-29
ZA201601362B (en) 2017-05-31
RU2015145255A3 (da) 2019-08-12
PT2470199T (pt) 2019-08-07
JP2023012499A (ja) 2023-01-25
US20130078231A1 (en) 2013-03-28
ES2902229T3 (es) 2022-03-25
KR20120081077A (ko) 2012-07-18
JP2020090513A (ja) 2020-06-11
KR102608546B1 (ko) 2023-12-04
US20210077593A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
DK2470199T3 (da) Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2726141T3 (da) Enhed til oral levering af terapeutiske forbindelser
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
ZA201301601B (en) Treatment of diseases
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK3045474T3 (da) Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation
EP2557921A4 (en) METHOD FOR TREATING RESPIRATORY BREATHING DURING SLEEPING
DK2381965T3 (da) Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom
EP2613786A4 (en) TREATMENT OF DISEASES
ZA201205829B (en) Treatment of respiratory disorders
DK2701733T3 (da) Forbindelser til behandling af neuropsykiatriske forstyrrelser
DK2506712T3 (da) Morfinanderivater til behandling af lægemiddeloverdosering
DK2717692T3 (da) Tetrahydrocannabinol-11-syrer til anvendelse til behandling af fibrotiske sygdomme
EP2771007A4 (en) TREATMENT OF RHINITIS
IT1402865B1 (it) Procedimento per il trattamento di acqua contaminata
DK2554172T3 (da) Fremgangsmåde til behandling af sygdomme
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA201106076B (en) Treatment of insulin-resistant disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
IL231622B (en) A pharmaceutical preparation for the treatment of stubbornness
BR112012000101A2 (pt) carboidratos medicinais para tratamento de condições respiratórias